Overview
Neurolief develops non-invasive neuromodulation devices for the treatment of neurological and psychiatric conditions, including migraine and depression, using targeted electrical stimulation.
More in Neuromodulation
Latest industry news
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Aurenar Raises $5.7M to Bring Stroke Neuromodulation to the Recovery Room
2026-08-30 · Funding
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →